Teva Pharmaceutical Industries Ltd. ADR (TEVA) News
Filter TEVA News Items
TEVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TEVA News Highlights
- TEVA's 30 day story count now stands at 7.
- Over the past 22 days, the trend for TEVA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TEL, DRUG and ABBV are the most mentioned tickers in articles about TEVA.
Latest TEVA News From Around the Web
Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.
Teva to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceTEL AVIV, Israel, December 28, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). |
HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 ElectionsThe silly season is upon us. Not the holidays – but the election. We’re less than 11 months out from the Presidential vote, and the first primary, the Iowa GOP caucus, is less than 30 days away. Election years are the ‘known unknown’ of the US economy. We know they’re coming, we know the results can change everything, we know that every economic sector will react differently – but we never truly know how those changes will shake out. This cyclical truth of politics and financial markets informs |
Here’s Why Teva Pharmaceutical Industries Limited (TEVA) Rose in Q3Sound Shore Management, an investment management firm, has released its investor letter for the third quarter of 2023. A copy of the same can be downloaded here. In the third quarter, the Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) declined 2.01% and 1.94%, respectively outperforming the Russell 1000 Value Index (Russell Value) which […] |
My 5 Largest Portfolio Holdings for 2024This mix of growth and value stocks appears set to outperform -- and hopefully makes me a lot richer in the process. |
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and AsthmaTEL AVIV, Israel, December 14, 2023--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. |
FTC warns pharma companies on excessive drug patentingThe Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid ObesityTEL AVIV, Israel, December 06, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces that a post hoc analysis4 of two phase 3 clinical studies presented today at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. |
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentPARSIPPANY, N.J., November 30, 2023--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease. |
Teva Pharmaceutical upgraded to 'Buy' at UBSUBS upgraded Teva Pharmaceutical (TEVA) to Buy from Neutral and raised its price target on the stock to $13 per share. UBS sees Teva "uniquely positioned to undergo a significant transition" to a more brand-focused company. Yahoo Finance anchors Seana Smith and Diane King Hall break down UBS's call on Teva and the stock's recent gains. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
Roku upgraded, Lucid Group downgraded: Wall Street's top analyst callsRoku upgraded, Lucid Group downgraded: Wall Street's top analyst calls |